Neuraminidase inhibitors for influenza complications

Chris Del Mar, Peter Doshi, Rokuro Hama, Mark Jones, Tom Jefferson, Carl Heneghan, Igho Onakpoya, Jeremy Howick

Research output: Contribution to journalLetterResearchpeer-review

Abstract

In their Comment (Aug 2, p 386),1 Jonathan Nguyen-Van-Tam and colleagues suggest that findings from our Cochrane review2 and a study of observational data3 are consistent. In our review, which was based on full clinical study reports of all manufacturer-sponsored randomised trials, we did not find evidence that neuraminidase inhibitors improve important outcomes of influenza, whereas the Roche-funded individual analysis of a subset of retrospective case reports suggested that neuraminidase inhibitors do have some beneficial effect.
Original languageEnglish
Pages (from-to)1260-1261
Number of pages2
JournalThe Lancet
Volume384
Issue number9950
DOIs
Publication statusPublished - 4 Oct 2014

Fingerprint

Neuraminidase
Human Influenza
Observational Studies
Clinical Studies

Cite this

Del Mar, C., Doshi, P., Hama, R., Jones, M., Jefferson, T., Heneghan, C., ... Howick, J. (2014). Neuraminidase inhibitors for influenza complications. The Lancet, 384(9950), 1260-1261. https://doi.org/10.1016/S0140-6736(14)61761-X
Del Mar, Chris ; Doshi, Peter ; Hama, Rokuro ; Jones, Mark ; Jefferson, Tom ; Heneghan, Carl ; Onakpoya, Igho ; Howick, Jeremy. / Neuraminidase inhibitors for influenza complications. In: The Lancet. 2014 ; Vol. 384, No. 9950. pp. 1260-1261.
@article{ce13c549c7664345a06f9129b00b20e5,
title = "Neuraminidase inhibitors for influenza complications",
abstract = "In their Comment (Aug 2, p 386),1 Jonathan Nguyen-Van-Tam and colleagues suggest that findings from our Cochrane review2 and a study of observational data3 are consistent. In our review, which was based on full clinical study reports of all manufacturer-sponsored randomised trials, we did not find evidence that neuraminidase inhibitors improve important outcomes of influenza, whereas the Roche-funded individual analysis of a subset of retrospective case reports suggested that neuraminidase inhibitors do have some beneficial effect.",
author = "{Del Mar}, Chris and Peter Doshi and Rokuro Hama and Mark Jones and Tom Jefferson and Carl Heneghan and Igho Onakpoya and Jeremy Howick",
year = "2014",
month = "10",
day = "4",
doi = "10.1016/S0140-6736(14)61761-X",
language = "English",
volume = "384",
pages = "1260--1261",
journal = "Lancet",
issn = "0140-6736",
publisher = "Elsevier",
number = "9950",

}

Del Mar, C, Doshi, P, Hama, R, Jones, M, Jefferson, T, Heneghan, C, Onakpoya, I & Howick, J 2014, 'Neuraminidase inhibitors for influenza complications' The Lancet, vol. 384, no. 9950, pp. 1260-1261. https://doi.org/10.1016/S0140-6736(14)61761-X

Neuraminidase inhibitors for influenza complications. / Del Mar, Chris; Doshi, Peter; Hama, Rokuro; Jones, Mark; Jefferson, Tom; Heneghan, Carl; Onakpoya, Igho; Howick, Jeremy.

In: The Lancet, Vol. 384, No. 9950, 04.10.2014, p. 1260-1261.

Research output: Contribution to journalLetterResearchpeer-review

TY - JOUR

T1 - Neuraminidase inhibitors for influenza complications

AU - Del Mar, Chris

AU - Doshi, Peter

AU - Hama, Rokuro

AU - Jones, Mark

AU - Jefferson, Tom

AU - Heneghan, Carl

AU - Onakpoya, Igho

AU - Howick, Jeremy

PY - 2014/10/4

Y1 - 2014/10/4

N2 - In their Comment (Aug 2, p 386),1 Jonathan Nguyen-Van-Tam and colleagues suggest that findings from our Cochrane review2 and a study of observational data3 are consistent. In our review, which was based on full clinical study reports of all manufacturer-sponsored randomised trials, we did not find evidence that neuraminidase inhibitors improve important outcomes of influenza, whereas the Roche-funded individual analysis of a subset of retrospective case reports suggested that neuraminidase inhibitors do have some beneficial effect.

AB - In their Comment (Aug 2, p 386),1 Jonathan Nguyen-Van-Tam and colleagues suggest that findings from our Cochrane review2 and a study of observational data3 are consistent. In our review, which was based on full clinical study reports of all manufacturer-sponsored randomised trials, we did not find evidence that neuraminidase inhibitors improve important outcomes of influenza, whereas the Roche-funded individual analysis of a subset of retrospective case reports suggested that neuraminidase inhibitors do have some beneficial effect.

UR - http://www.scopus.com/inward/record.url?scp=84925286600&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(14)61761-X

DO - 10.1016/S0140-6736(14)61761-X

M3 - Letter

VL - 384

SP - 1260

EP - 1261

JO - Lancet

JF - Lancet

SN - 0140-6736

IS - 9950

ER -

Del Mar C, Doshi P, Hama R, Jones M, Jefferson T, Heneghan C et al. Neuraminidase inhibitors for influenza complications. The Lancet. 2014 Oct 4;384(9950):1260-1261. https://doi.org/10.1016/S0140-6736(14)61761-X